Larimar Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2023 Annual Meeting of Stockholders held virtually on May 9, 2023. The record date for the meeting was March 30, 2023, with 43,269,200 outstanding shares of common stock entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were submitted to stockholders, all of which were approved:
- Proposal 1 (Election of Class III Directors): Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt were elected to serve until the 2026 Annual Meeting. Significant broker non-votes (4,876,931) were recorded for all three candidates.
- Proposal 2 (Advisory Executive Compensation): Stockholders approved the 2022 compensation of named executive officers. The vote was 35,507,612 for, 337,895 against, and 55,741 abstentions.
- Proposal 3 (Ratification of Auditors): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the 2023 fiscal year was ratified overwhelmingly with 40,769,530 votes for and only 6,201 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 11, 2023, for detailed background on the director nominees and executive compensation.
- Confirm the total number of outstanding shares and voting rights as of the March 30, 2023 record date.
- Review the specific terms of the engagement with PricewaterhouseCoopers LLP for the 2023 fiscal year.